All In Biotech

Drug Trial Radar · NCT07820085

A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)

A Phase 2b/3, Quadruple-Blinded, Randomized, Placebo-Controlled Study of PORT-77 Administered Orally to Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria and an Open-Label Extension

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

225

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Mar 2029

Study completion Sep 2029

Sponsor

Lead sponsor
Portal Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PATHWAY is a Phase 2b/3 clinical study with an Open-Label Extension (OLE). It tests PORT-77 in patients with EPP, EPP2, and XLP. The study has three parts: Part 1: Phase 2b * Find the right dose of PORT-77 to lower PPIX levels in the blood * Test if PORT-77 lowers PPIX levels better than placebo * Check the safety of each dose Part 2: Phase 3 * Test if PORT-77 lowers PPIX levels better than placebo * Test if PORT-77 increases the amount of time patients spend in sunlight each day without pain compared to placebo * Check the safety of PORT-77 Part 3: Open-Label Extension (OLE) * Test the long-term effect of PORT-77 on PPIX levels and time in sun * Monitor long-term safety

Conditions

  • Erythropoietic Protoporphyria (EPP)
  • X-Linked Protoporphyria (XLP)
  • EPP2

Interventions

  • PORT-77Drug

    Oral tablets

  • PlaceboDrug

    Oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma metal-free PPIX concentration changeTime frame: Part 1 - Days 1 through 84; Part 2 - through Day 182; Part 3 - through Month 12
  2. Adverse EventsTime frame: Part 1 - Day 1 through Day 84; Part 2 - through Day 182; Part 3 - through Month 12
  3. Average daily time in sunlight without painTime frame: Part 2 - Day 155 through 182

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Investigative Site

    Huntington Beach, California · Recruiting

  • Investigative Site

    Cincinnati, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.